“p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities”. Molecular Cell2 (3): 305–16. (September 1998). doi:10.1016/S1097-2765(00)80275-0. PMID9774969.
“Cloning and functional analysis of human p51, which structurally and functionally resembles p53”. Nature Medicine4 (7): 839–43. (July 1998). doi:10.1038/nm0798-839. PMID9662378.
“p53CP is p51/p63, the third member of the p53 gene family: partial purification and characterization”. Carcinogenesis22 (2): 295–300. (February 2001). doi:10.1093/carcin/22.2.295. PMID11181451.
“Dedicated protection for the female germline”. Nature Reviews Molecular Cell Biology8 (1): 4–5. (January 2007). doi:10.1038/nrm2091.
“PERP-ing into diverse mechanisms of cancer pathogenesis: Regulation and role of the p53/p63 effector PERP”. Biochim Biophys Acta Rev Cancer1874 (1): 188393. (Dec 2020). doi:10.1016/j.bbcan.2020.188393. PMID32679166.
“Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate”. The American Journal of Surgical Pathology31 (6): 889–94. (June 2007). doi:10.1097/01.pas.0000213447.16526.7f. PMID17527076.
“Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach”. Modern Pathology18 (1): 111–8. (January 2005). doi:10.1038/modpathol.3800251. PMID15309021.
Martin SE, Temm CJ, Goheen MP, Ulbright TM, Hattab EM (2011). “Cytoplasmic p63 immunohistochemistry is a useful marker for muscle differentiation: an immunohistochemical and immunoelectron microscopic study.”. Mod Pathol24 (10): 1320–6. doi:10.1038/modpathol.2011.89. PMID21623385.
“P63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome”. The Journal of Biological Chemistry278 (26): 23906–14. (June 2003). doi:10.1074/jbc.M300746200. PMID12692135.
“p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities”. Molecular Cell2 (3): 305–16. (September 1998). doi:10.1016/S1097-2765(00)80275-0. PMID9774969.
“Cloning and functional analysis of human p51, which structurally and functionally resembles p53”. Nature Medicine4 (7): 839–43. (July 1998). doi:10.1038/nm0798-839. PMID9662378.
“p53CP is p51/p63, the third member of the p53 gene family: partial purification and characterization”. Carcinogenesis22 (2): 295–300. (February 2001). doi:10.1093/carcin/22.2.295. PMID11181451.
“DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development”. Cancer Research63 (10): 2351–7. (May 2003). PMID12750249.
“PERP-ing into diverse mechanisms of cancer pathogenesis: Regulation and role of the p53/p63 effector PERP”. Biochim Biophys Acta Rev Cancer1874 (1): 188393. (Dec 2020). doi:10.1016/j.bbcan.2020.188393. PMID32679166.
“p63 as a complementary basal cell specific marker to high molecular weight-cytokeratin in distinguishing prostatic carcinoma from benign prostatic lesions”. The Medical Journal of Malaysia62 (1): 36–9. (March 2007). PMID17682568.
“Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate”. The American Journal of Surgical Pathology31 (6): 889–94. (June 2007). doi:10.1097/01.pas.0000213447.16526.7f. PMID17527076.
“Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach”. Modern Pathology18 (1): 111–8. (January 2005). doi:10.1038/modpathol.3800251. PMID15309021.
Martin SE, Temm CJ, Goheen MP, Ulbright TM, Hattab EM (2011). “Cytoplasmic p63 immunohistochemistry is a useful marker for muscle differentiation: an immunohistochemical and immunoelectron microscopic study.”. Mod Pathol24 (10): 1320–6. doi:10.1038/modpathol.2011.89. PMID21623385.
“P63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome”. The Journal of Biological Chemistry278 (26): 23906–14. (June 2003). doi:10.1074/jbc.M300746200. PMID12692135.